Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 622 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sedentary Control Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Using Electrophysiology to Index Non-invasive Brain Stimulation Effects on Reward System Functioning in Depression

NCT05194098
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
TMS: single session intermittent theta burst stimulation (iTBS) to dorsomedial prefrontal target in individuals with major depressive disorder, via MagVenture MagPro R30 device / Cool-DB80 A/P coil, SHAM (inactive) TMS stimulation
Device
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 17, 2026, 9:11 PM EDT
Completed Phase 1 Interventional

A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)

NCT04891965
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
ART24, Placebo
Biological · Drug
Lead sponsor
Adiso Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Palm Springs, California • Clearwater, Florida • Doral, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 17, 2026, 9:11 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

NCT02753400
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
emixustat hydrochloride, Placebo
Drug · Other
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 17, 2026, 9:11 PM EDT
Completed Phase 2 Interventional

Effects of Resistance and Aerobic Exercise on Cardiovascular Health

NCT00275145
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Obesity, Hyperlipidemia, Insulin Resistance, Metabolic Syndrome X
Interventions
Resistance Training, Aerobic Exercise, Combo, Continued Sedentary lifestyle
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 24, 2013 · Synced Oct 17, 2026, 9:11 PM EDT
Completed Phase 2 Interventional Results available

Insomnia Treatment and EMA (Ecological Momentary Assessment) Outcomes

NCT05908526
View directory record Official record
Conditions
Insomnia
Interventions
Baseline surveys, Cognitive testing and EMAs, Actiwatch, suvorexant (or placebo), Placebo
Behavioral · Device · Drug + 1 more
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
60 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 17, 2026, 9:11 PM EDT
Completed Phase 4 Interventional Results available

Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression

NCT01479829
View directory record Official record
Conditions
Bipolar Depression
Interventions
Escitalopram, Celecoxib, Placebo
Drug
Lead sponsor
Loyola University
Other
Eligibility
21 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 17, 2026, 9:11 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Physical Activity and Education Program for Somali Women

NCT02254902
View directory record Official record
Conditions
Sedentary Lifestyle
Interventions
Physical Activity intervention
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 17, 2026, 9:11 PM EDT
Terminated Phase 2 Interventional

Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT03676231
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
SGM-1019, Placebo
Drug
Lead sponsor
Second Genome
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
10
States / cities
Chandler, Arizona • Tucson, Arizona • Panorama City, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 17, 2026, 9:11 PM EDT
Completed Phase 2 Interventional Results available

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults

NCT03265288
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LAU-7b, Placebo oral capsule
Drug
Lead sponsor
Laurent Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
27
States / cities
Long Beach, California • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 17, 2026, 9:11 PM EDT
Completed Not applicable Interventional

Impact of Biophoton Generator on Chronic-Stroke Patients' Recovery

NCT05898334
View directory record Official record
Conditions
Chronic Stroke, Paralysis
Interventions
Active Biophoton Generators, Inactive Biophoton Generators
Device
Lead sponsor
First Institute of All Medicines
Other
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Butler, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 17, 2026, 9:11 PM EDT
Completed Not applicable Interventional

teleABLE to Reduce Post-Stroke Sedentary Behavior

NCT06312709
View directory record Official record
Conditions
Stroke
Interventions
teleABLE (telehealth-delivered Activating Behavior for Lasting Engagement), Health Education
Behavioral · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 17, 2026, 9:11 PM EDT
Completed Not applicable Interventional Results available

A Mobile Intervention to Reduce Pain and Improve Health (MORPH)

NCT03377634
View directory record Official record
Conditions
Chronic Pain, Obesity, Sedentary Lifestyle
Interventions
MORPH
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years to 79 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 17, 2026, 9:11 PM EDT
Completed Phase 2 Interventional Results available

Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)

NCT03865732
View directory record Official record
Conditions
PCDH19-Related Epilepsy
Interventions
Ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
1 Year to 17 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 17, 2026, 9:11 PM EDT
Terminated Phase 1 Interventional

BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES

NCT03658135
View directory record Official record
Conditions
Primary Tauopathies, Corticobasal Degeneration Syndrome, Frontotemporal Lobar Degeneration With Tau Inclusions, MAPT Mutation Carriers, Symptomatic, Traumatic Encephalopathy Syndrome, Nonfluent Aphasia, Progressive
Interventions
BIIB092, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
35 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Oct 17, 2026, 9:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks

NCT00373399
View directory record Official record
Conditions
Marijuana Use Disorder
Interventions
Inactive Marijuana (0% THC), Low THC marijuana (1.8 %THC), High THC marijuana (3.9% THC)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 17, 2026, 9:11 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

NCT05616221
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Interventions
AP-PA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Farmington, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 17, 2026, 9:11 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1)

NCT04599478
View directory record Official record
Conditions
Loss-of-control Eating, Obesity/Overweight
Interventions
Naltrexone and Bupropion medication, Behavioral Weight Loss, Placebo
Drug · Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 17, 2026, 9:11 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

NCT02836873
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
20 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Fresno, California • La Palma, California • Lincoln, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 17, 2026, 9:11 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease

NCT03808103
View directory record Official record
Conditions
Crohn Disease
Interventions
Placebo, Bacteriophage preparation
Biological
Lead sponsor
Intralytix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
2
States / cities
Lutherville, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2025 · Synced Oct 17, 2026, 9:11 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Down Syndrome Memantine Follow-up Study

NCT02304302
View directory record Official record
Conditions
Down Syndrome, Intellectual Disability
Interventions
Memantine, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
15 Years to 32 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 17, 2026, 9:11 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis

NCT01824303
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
LiRIS 400 mg, LiRIS Placebo
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Glendora, California • Daytona Beach, Florida • Kansas City, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2016 · Synced Oct 17, 2026, 9:11 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT06546670
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
ITU512, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 55 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
9
States / cities
Birmingham, Alabama • Miami, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 9:11 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Growth Hormone as a Determinant of Weight Regulation

NCT00355784
View directory record Official record
Conditions
Obesity
Interventions
overfeeding, growth hormone treatment
Other · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 35 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 17, 2026, 9:11 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Yoga for the Treatment of Metabolic Syndrome

NCT00605436
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Restorative yoga therapy
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2008 · Synced Oct 17, 2026, 9:11 PM EDT